For esophageal cancer specifically, its distinct immune microenvironment features, such as high rates of PD-L1 and PD-L2(Programmed Death-Ligand 2) expression, offer potential targets for immunotherapy (9). Here, PDCD1LG2 is linked to esophageal cancer.